U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H27N3O4
Molecular Weight 433.5005
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BELOTECAN

SMILES

CC[C@@]1(c2cc3-c4c(Cn3c(=O)c2COC1=O)c(CCNC(C)C)c5ccccc5n4)O

InChI

InChIKey=LNHWXBUNXOXMRL-VWLOTQADSA-N
InChI=1S/C25H27N3O4/c1-4-25(31)19-11-21-22-17(12-28(21)23(29)18(19)13-32-24(25)30)15(9-10-26-14(2)3)16-7-5-6-8-20(16)27-22/h5-8,11,14,26,31H,4,9-10,12-13H2,1-3H3/t25-/m0/s1

HIDE SMILES / InChI
Belotecan is a semisynthetic analogue of camptothecin containing a 2-(N-isopropylamino) ethyl group linkage at position C-7 of the camptothecin ring. It stabilizes the complex formed between topoisomerase I and DNA, thereby preventing the religation of DNA breaks. This leads to an inhibition of DNA replication and triggers apoptotic cell death. Belotecan was approved in Korea under the name Camtobell for the treatment of patients with ovarian and small cell lung cancers.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P11387|||Q9UJN0
Gene ID: 7150
Gene Symbol: TOP1
Target Organism: Homo sapiens (Human)
0.275000000000000022 µM [IC50]
Conditions
PubMed

PubMed

TitleDatePubMed
In vitro pharmacodynamics of CKD-602 in HT-29 cells.
2002 Oct
Safety pharmacology of CKD-602, a novel anticancer agent.
2003
Embryotoxic effects of CKD-602, a new camptothecin anticancer agent, in rats.
2005 May-Jun
The synergism between Belotecan and cisplatin in gastric cancer.
2006
Reproductive toxicity evaluation of a new camptothecin anticancer agent, CKD-602, in pregnant/lactating female rats and their offspring.
2007 Feb
A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer.
2007 Oct 15
Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells.
2008 Nov
Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer.
2009 Aug
Chemosensitivity of uterine cervical cancer demonstrated by the histoculture drug response assay.
2009 Dec
Apoptotic effect of CKD-602 (Camtobell) on oral squamous cell carcinoma cell lines.
2009 Mar
Gateways to clinical trials.
2009 Nov
Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
2009 Nov
Phase II study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer.
2009 Oct
Decreased urinary secretion of belotecan in folic acid-induced acute renal failure rats due to down-regulation of Oat1 and Bcrp.
2009 Oct
Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer.
2010 Jan 1
Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.
2010 Jun
A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer.
2010 Jun
Toxicity study of a new camptothecin anti-cancer agent CKD-602 in dogs: 4-week continuous intravenous dose by infusion pump and 4-week repeated intravenous dose.
2010 Nov
Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial.
2010 Oct
Patents

Sample Use Guides

Small cell lung cancer: 0.5mg/m2/day for day 1 to 4. Ovarian cancer: 0.5mg/m2 IV days 1, 2, 3, 4, 5 of each 21 day cycle until 6 cycle or disease progression.
Route of Administration: Intravenous
In a cell viability assay, human glioblastoma cell lines (U87 MG, U251 MG, U343 MG, LN229) were plated in 96-well plates at a density of 2x10(3) cells/well (100 ul). In each experimental set, cells were plated in quadruplicate and were treated with different concentrations (0.05, 0.1, 0.2, 0.5, 1, 2, 5 uM) of belotecan for 24, 48 and 72 h. The IC50 values were 84.66 nM for U87 MG cells, 29.13 nM for U343 MG, 14.57 nM for U251 MG cells and 9.07 nM for LN229 cells at 48 h after treatment.
Name Type Language
BELOTECAN
INN   MART.   MI   WHO-DD  
INN  
Official Name English
1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE, 4-ETHYL-4-HYDROXY-11-(2-((1-METHYLETHYL)AMINO)ETHYL)-, (4S)-
Systematic Name English
BELOTECAN [WHO-DD]
Common Name English
BELOTECAN [MART.]
Common Name English
BELOTECAN [MI]
Common Name English
(4S)-4-ETHYL-4-HYDROXY-11-(2-((1-METHYLETHYL)AMINO)ETHYL)-1,12-DIHYDRO-14H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H)-DIONE
Systematic Name English
BELOTECAN [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2843
Created by admin on Sat Jun 26 08:50:21 UTC 2021 , Edited by admin on Sat Jun 26 08:50:21 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C73305
Created by admin on Sat Jun 26 08:50:21 UTC 2021 , Edited by admin on Sat Jun 26 08:50:21 UTC 2021
PRIMARY
CAS
256411-32-2
Created by admin on Sat Jun 26 08:50:21 UTC 2021 , Edited by admin on Sat Jun 26 08:50:21 UTC 2021
PRIMARY
ChEMBL
CHEMBL2111084
Created by admin on Sat Jun 26 08:50:21 UTC 2021 , Edited by admin on Sat Jun 26 08:50:21 UTC 2021
PRIMARY
DRUG BANK
DB12459
Created by admin on Sat Jun 26 08:50:21 UTC 2021 , Edited by admin on Sat Jun 26 08:50:21 UTC 2021
PRIMARY
EVMPD
SUB32250
Created by admin on Sat Jun 26 08:50:21 UTC 2021 , Edited by admin on Sat Jun 26 08:50:21 UTC 2021
PRIMARY
DRUG CENTRAL
296
Created by admin on Sat Jun 26 08:50:21 UTC 2021 , Edited by admin on Sat Jun 26 08:50:21 UTC 2021
PRIMARY
EPA CompTox
256411-32-2
Created by admin on Sat Jun 26 08:50:21 UTC 2021 , Edited by admin on Sat Jun 26 08:50:21 UTC 2021
PRIMARY
PUBCHEM
6456014
Created by admin on Sat Jun 26 08:50:21 UTC 2021 , Edited by admin on Sat Jun 26 08:50:21 UTC 2021
PRIMARY
FDA UNII
27Z82M2G1N
Created by admin on Sat Jun 26 08:50:21 UTC 2021 , Edited by admin on Sat Jun 26 08:50:21 UTC 2021
PRIMARY
MERCK INDEX
M2298
Created by admin on Sat Jun 26 08:50:21 UTC 2021 , Edited by admin on Sat Jun 26 08:50:21 UTC 2021
PRIMARY Merck Index
INN
8483
Created by admin on Sat Jun 26 08:50:21 UTC 2021 , Edited by admin on Sat Jun 26 08:50:21 UTC 2021
PRIMARY
WIKIPEDIA
BELOTECAN
Created by admin on Sat Jun 26 08:50:21 UTC 2021 , Edited by admin on Sat Jun 26 08:50:21 UTC 2021
PRIMARY
MESH
C116963
Created by admin on Sat Jun 26 08:50:21 UTC 2021 , Edited by admin on Sat Jun 26 08:50:21 UTC 2021
PRIMARY